extrapyramidal

PAOPA is a novel dopamine D2 receptor modulator and L-proline-L-leucine-glycine amide (PLG) peptide mimetic that prevents and reverses behavioral and biochemical abnormalities in preclinical animal models of schizophrenia sensitized to amphetamine. PAOPA has been used in the study of schizophrenia and extrapyramidal dysfunction.

Prochlorperazine Maleate (Capazine) is a phenothiazine antipsychotic used principally in the treatment of NAUSEA; VOMITING; and VERTIGO. It is more likely than CHLORPROMAZINE to cause EXTRAPYRAMIDAL DISORDERS.

Diphenhydramine (Syntedril), a first-generation antihistamine possessing antiemetic, antitussive, anticholinergic, and sedative properties, is mainly used in the treatment of allergies. Diphenhydramine is also used in the management of drug-induced parkinsonism and other extrapyramidal symptoms.

Biperiden (Bipariden) is a muscarinic antagonist that has effects in both the central and peripheral nervous systems. It has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism. It has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine.

Blonanserin (AD-5423) is an atypical antipsychotic approved in Japan in January, 2008. Relative to many other antipsychotics, blonanserin has an improved tolerability profile, lacking side effects such as extrapyramidal symptoms, excessive sedation, or hypotension.

Pericyazine (Propericiazine) is a selective D2-dopamine receptor antagonist. Pericyazine is a first-generation antipsychotic drug that is used as an adjunct to the short-term management of severe anxiety states and psychosis.

Eticlopride, an antipsychotic, is a Selective dopamine D2 D3 receptor antagonist (Ki: 0.5 0.16 nM).

Tropatepine is an orally active antagonist of anticholinergic muscarinic. Tropatepine is an antiparkinsonian agent that can be used to combat against extrapyramidal syndrome caused by neuroleptic drugs [1][2].

Blonanserin-d5 is a deuterated compound of Blonanserin. Blonanserin has a CAS number of 132810-10-7. Blonanserin is an atypical antipsychotic approved in Japan in January, 2008. Relative to many other antipsychotics, blonanserin has an improved tolerability profile, lacking side effects such as extrapyramidal symptoms, excessive sedation, or hypotension.